NYSE:RCUSBiotechs
How Investors May Respond To Arcus Biosciences (RCUS) Expanding ARC-20 With New Kidney Cancer Combo
Arcus Biosciences and Summit Therapeutics previously announced a clinical trial collaboration to test Arcus’s oral HIF-2a inhibitor casdatifan with Summit’s PD-1/VEGF bispecific antibody ivonescimab in metastatic clear cell renal cell carcinoma, adding a new combination cohort to Arcus’s ongoing ARC-20 platform study.
An interesting aspect of this collaboration is that both companies retain full rights to their own drugs while sharing study costs, potentially expanding each firm’s kidney...